The Enterprise Value as of November 2024 (TTM) for Agios Pharmaceuticals, Inc. (AGIO) is 2.98B

According to Agios Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.98B. This represents a change of 57.25% compared to the average of 1.90B of the last 4 quarters.

Agios Pharmaceuticals, Inc. (AGIO) Historical Enterprise Value (quarterly & annually)

How has AGIO Enterprise Value performed in the past?

The mean historical Enterprise Value of Agios Pharmaceuticals, Inc. over the last ten years is 2.13B. The current 2.98B Enterprise Value has changed 13.93% with respect to the historical average. Over the past ten years (40 quarters), AGIO's Enterprise Value was at its highest in in the June 2018 quarter at 4.65B. The Enterprise Value was at its lowest in in the June 2016 quarter at 1.08B.

Agios Pharmaceuticals, Inc. (AGIO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Agios Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Agios Pharmaceuticals, Inc. (AGIO) Average Enterprise Value

How has AGIO Enterprise Value performed in the past?

The current Enterprise Value of Agios Pharmaceuticals, Inc. (AGIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Agios Pharmaceuticals, Inc. (AGIO) Enterprise Value vs. Peers

How is AGIO’s Enterprise Value compared to its peers?

Agios Pharmaceuticals, Inc.’s Enterprise Value is greater than Mereo BioPharma Group plc (496.22M), less than Blueprint Medicines Corporation (6.36B), greater than Day One Biopharmaceuticals, Inc. (963.46M), less than BioMarin Pharmaceutical Inc. (12.17B), greater than IDEAYA Biosciences, Inc. (1.93B), greater than AnaptysBio, Inc. (502.56M), greater than MeiraGTx Holdings plc (427.31M), greater than Keros Therapeutics, Inc. (1.75B), greater than Homology Medicines, Inc. (-103303255.00), greater than Kymera Therapeutics, Inc. (2.89B), less than Revolution Medicines, Inc. (9.43B), greater than C4 Therapeutics, Inc. (307.45M), greater than Nurix Therapeutics, Inc. (1.49B), greater than Relay Therapeutics, Inc. (692.53M), greater than Stoke Therapeutics, Inc. (457.69M), greater than Pliant Therapeutics, Inc. (770.48M), greater than Black Diamond Therapeutics, Inc. (139.97M), greater than Arvinas, Inc. (1.69B), greater than Syndax Pharmaceuticals, Inc. (1.24B), greater than Cogent Biosciences, Inc. (929.30M), greater than Cullinan Oncology, Inc. (630.54M), greater than KalVista Pharmaceuticals, Inc. (468.87M), greater than Mersana Therapeutics, Inc. (204.64M),

Build a custom stock screener for Agios Pharmaceuticals, Inc. (AGIO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Agios Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Agios Pharmaceuticals, Inc. (AGIO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Agios Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.